{"id":4474,"date":"2014-09-26T12:00:26","date_gmt":"2014-09-26T11:00:26","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=4474"},"modified":"2014-10-23T12:53:49","modified_gmt":"2014-10-23T11:53:49","slug":"samarbeid-mellom-akademia-og-legemiddelindustri","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2014\/09\/26\/samarbeid-mellom-akademia-og-legemiddelindustri\/","title":{"rendered":"Samarbeid mellom akademia og legemiddelindustriCooperation between academia and the pharmaceutical industry"},"content":{"rendered":"

\"Roland<\/a>Fra flere hold legges det opp til mer samarbeid mellom akademia og legemiddelindustri ikke minst gjennom Horizon 2020. Dette er et ikke tilstrekkelig benyttet innovativt middel for ogs\u00e5 \u00e5 styrke forskningen ved v\u00e5re universitetsklinikker. Bransjeforeningen for legemiddelindustrien (LMI) i Norge kan i dette sammenheng v\u00e6re behjelpelig til\/med slikt samarbeid. LMI representerer ca. 60 medlemsfirmaer som best\u00e5r av b\u00e5de internasjonale selskaper og sm\u00e5 biotekforetak.\u00a0 Bedriftene sysselsetter ca. 4000 h\u00f8ykompetent arbeidskraft der ogs\u00e5 noen medlemsbedrifter har egen produksjon i Norge.<\/p>\n

Demografiske endringer og endret sykdomsbilde gir helse og omsorgssektoren utfordringer som krever bedre resursutnyttelse, h\u00f8yere effektivitet samt nye og bedre tjenester. Ny teknologi og produktutvikling vil v\u00e6re avgj\u00f8rende f\u00f8r \u00e5 m\u00f8te nye krav, opprettholde kvaliteten p\u00e5 helsetjenestene samt m\u00f8te forventninger om gode velferdstjenester og god behandling.\u00a0 I disse utfordringene ligger det ogs\u00e5 et stort potensial for verdiskapning og innovasjon. Biomedisinsk og helserelatert forskning kan m\u00f8te disse helseutfordringene.<\/p>\n

Hva kjennetegner n\u00e5situasjonen? Jo, vi har h\u00f8y forskningsinnsats men b\u00e5de lav innovasjon og altfor lav deltakelse fra n\u00e6ringslivet. Fra HelseOmsorg21<\/a> strategien oppfordres vi til f\u00f8lgende: \u00d8kt samhandling mellom n\u00e6ringsliv og det offentlige. Til \u00e5 begynne med \u00f8kt dialog og partnerskap. \u00d8nske om st\u00f8rre medvirkning fra n\u00e6ringslivet i norsk helseforskning. St\u00f8rre fokus p\u00e5 kommersialisering av forskning. \u00d8kt antall industrifinansierte kliniske studier. Utnyttelse av helsedata som nasjonalt fortrinn.<\/p>\n

Politikerne m\u00e5 derfor legge til rette for \u00f8kt antall selskapsetableringer og gode utviklingsk\u00e5r for norsk helseindustri. Samtidig er legemiddelindustrien p\u00e5 jakt etter \u00f8kt produktivitet og vitenskapelig eksellense! Dette kan v\u00e6re noe som v\u00e5re stipendiater og post-doc kan gripe an i sin karriereplanlegging.<\/p>\n

Roland\"Roland<\/a>More collaboration between academia and the pharmaceutical industry is increasingly encouraged, not least through Horizon 2020. This innovative possibility to strengthen the research with our university clinics has not been sufficiently utilized.\u00a0 The Association of the Pharmaceutical Industry in Norway (LMI) may, in this context, provide assistance in establishing such collaboration. LMI represents about 60 membership companies consisting of both international companies as well as smaller biotech enterprises. The companies employ approximately 4000 highly skilled staff where some membership companies also have their own production in Norway.<\/p>\n

Demographic changes and an altered panorama of diseases provide the healthcare sector with challenges demanding better utilization of resources, higher efficiency as well as new and improved services. New technology and product development are keys to face new demands, maintain the quality of the health services as well as meet expectations for good welfare services and proper treatments. Within these challenges there is also a major potential for the creation of wealth and innovation. Biomedical and health-related research can meet these health challenges.<\/p>\n

What characterizes the current situation? Sure, we have high research activity, but low innovation and way too low inclusion of the private sector. From the HelseOmsorg21<\/a> (in Norwegian) strategy we are encouraged to: Increase cooperation between the private and public sectors. More focus on commercialization of research. Increase the number of industrially funded clinical studies. The utilization of health data as a national asset.<\/p>\n

The politicians thus have to provide the foundations for increasing the number of start-ups, as well as provide proper development conditions for Norwegian health industry. Simultaneously, the pharmaceutical industry is aiming for higher productivity and scientific excellence. This could be something that our PhD-candidates and post-docs could embrace in their career planning.<\/p>\n

Roland<\/p>","protected":false},"excerpt":{"rendered":"

Fra flere hold legges det opp til mer samarbeid mellom akademia og legemiddelindustri ikke minst gjennom Horizon 2020. Dette er et ikke tilstrekkelig benyttet innovativt middel for ogs\u00e5 \u00e5 styrke forskningen ved v\u00e5re universitetsklinikker. Bransjeforeningen for legemiddelindustrien (LMI) i Norge…<\/p>\n

Read more →<\/a><\/p>","protected":false},"author":2781,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44,39969],"tags":[52331],"class_list":["post-4474","post","type-post","status-publish","format-standard","hentry","category-nyheter","category-ukens-leder","tag-52331"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/4474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/2781"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=4474"}],"version-history":[{"count":6,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/4474\/revisions"}],"predecessor-version":[{"id":4490,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/4474\/revisions\/4490"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=4474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=4474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=4474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}